

Table S1. Comedication during HCV therapy in >3% patients (ATC Level 4, chemical subgroup).

| | ITT total % |
|---|-------------|
| N07BC: Drugs used in opioid dependence | 25.9% |
| C07AB: Beta blocking agents, selective | 6.1% |
| N02AE: Oripavine derivatives | 5.7% |
| C09AA: ACE inhibitors, plain | 5.7% |
| A02BC: Proton pump inhibitors | 5.6% |
| H03AA: Thyroid hormones | 4.4% |
| C08CA: Dihydropyridine derivatives | 4.0% |
| M02AA: Anti-inflammatory preparations, non-steroids for topical use | 3.9% |
| M01AE: Propionic acid derivatives | 3.7% |
| A11CC: Vitamin D and analogues | 3.7% |
| B01AC: Platelet aggregation inhibitors excl. heparin | 3.6% |
| G02CC: Anti-inflammatory products for vaginal administration | 3.5% |
| N02BA: Salicylic acid and derivatives | 3.5% |
| A01AD: Other agents for local oral treatment | 3.5% |
| N06AX: Other antidepressants | 3.4% |

ATC, Anatomic Therapeutic Chemical; ACE, angiotensin-converting enzyme.

Table S2. Overlap between OST or active drug use, and other populations of special interest (total population).

| Combination of subgroups | Number of patients (N = 2354) |
|---|----------------------------------|
| OST + alcohol use | 71 |
| OST + active drug use | 69 |
| OST + psychiatric comorbidity | 122 |
| Alcohol use + PWUD (active) | 22 |
| Alcohol use + psychiatric comorbidity | 46 |
| PWUD (active) + psychiatric comorbidity | 27 |
| OST + alcohol use + PWUD (active) | 16 |
| OST + alcohol use + psychiatric comorbidity | 20 |
| Alcohol use + PWUD (active) + psychiatric comorbidity | 6 |
| OST + alcohol use + PWUD (active) + psychiatric comorbidity | 4 |
| Migrants + PWUD (active) | 26 |
| CIS-migrants + PWUD (active) | 12 |
| Migrants + OST | 191 |
| CIS-migrants + OST | 105 |
| Migrants + PWUD (active) + OST | 24 |
| CIS-migrants + PWUD (active) + OST | 11 |

CIS, Commonwealth of Independent States; OST, opioid substitution therapy; PWUD (active), people who actively use drugs.




Figure S1. Estimated length of HCV infection.

Data are median (IQR) with min and max values. CIS, Commonwealth of Independent States; HIV, human immunodeficiency virus; OST, opioid substitution therapy; PWUD (active), people who actively use drugs.





Figure S2. Patient disposition.

EP-ITT, intention-to-treat in the effectiveness population; EP-mITT, modified ITT in the effectiveness population FU, follow-up; PTW, post-treatment week; SVR12, sustained virologic response at post-treatment Week 12

A



B




Figure S3. SVR12 rates in treatment-naïve patients with CC by genotype for (A) 8-week treatment with G/P and (B) 12-week treatment with G/P.

CC, compensated cirrhosis; G/P, glecaprevir/pibrentasvir; GT, genotype; HCV, hepatitis C virus; ITT, intention to treat; mITT, modified ITT; SVR, sustained virologic response at post-treatment Week 12.




Figure S4. Mean SF-36 scores from baseline to PTW12 (A) Physical component summary score (B) Mental component summary score.

CIS, Commonwealth of Independent States; HCV, hepatitis C virus; HIV, human immunodeficiency virus; OST, opioid substitution therapy; PWUD (active), people who actively use drugs.




Figure S5. Compliance of patients who completed treatment, as judged by physicians at the end of therapy.

CIS, Commonwealth of Independent States; HIV, human immunodeficiency virus; OST, opioid substitution therapy; PWUD (active), people who actively use drugs.